Atamyo Therapeutics SAS

ReCode Therapeutics , on track with its plan to take its two lead programs into the clinic this year, announced on 19 September that it raised another $50m in series B venture capital, bringing the ro

Genethon may not be a traditional biotech, but as a non-profit it had research and intellectual property incorporated into Novartis AG ’s gene therapy Zolgensma (onasemnogene abeparvovec), and now h